TFX Teleflex Incorporated

Teleflex Incorporated Announces Benson Smith to Retire as Chief Executive Officer at End of 2017; Liam Kelly to Succeed Smith as Chief Executive Officer

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announced today that Benson Smith will retire from his position as Chief Executive Officer, effective on December 31, 2017. Mr. Smith, a Teleflex Board member since 2005, will continue to serve as Teleflex’s Chairman of the Board. He has been nominated by Teleflex’s Board of Directors to serve for another three year term if elected by Teleflex’s stockholders at the 2017 annual meeting to be held in May, 2017.

“I want to thank the Board of Directors, along with all of our employees and shareholders, for the opportunity to serve on the executive management team at Teleflex,” said Mr. Smith. “When I began my tenure as CEO in 2011, Teleflex was completing its transition from a diversified industrial company, and I’m proud that in less than a decade we have been able to successfully grow into our current position as a leading global provider of medical devices. I have tremendous confidence in my colleague, Liam Kelly, and the talented executives that we have been able to attract and develop at Teleflex, and I look forward to Teleflex’s continued success under Liam’s leadership and strategic guidance.”

Liam Kelly, who currently serves as Teleflex’s President and Chief Operating Officer, has been named by the Teleflex Board of Directors to succeed Mr. Smith as Chief Executive Officer following Mr. Smith’s retirement.

“I’m grateful to Benson for his years of leadership as CEO, under which Teleflex has continuously expanded and improved its capabilities as a diversified, global provider of medical technologies, and I’m excited by the prospect of leading Teleflex through the Company’s next stage of growth and development,” said Mr. Kelly.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, statements related to the occurrence of, and arrangements related to, Mr. Smith’s retirement as, and Mr. Kelly’s designation as, Teleflex’s Chief Executive Officer.. Actual results could differ materially from those in the forward-looking statements due to, among other things, the stockholder vote at Teleflex’s 2017 annual meeting and other factors described or incorporated in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2015.

EN
23/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a...

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for pur...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch